Among these genes, ROS1 was reported as an oncogenic driver in lung cancer (Rikova et al., 2007), and tyrosine kinase inhibitors (TKIs) targeting ROS1 have been found to block tumor growth and provide clinical benefits for patients (D'Angelo et al., 2020; Shaw et al., 2014). This evidence concerns the gene ROS1 and neoplasm.